Novo Nordisk A/S (NYSE:NVO) has reportedly filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss drug, Wegovy. This move brings the total number of lawsuits by the Danish drugmaker to 21 since June, with five sellers already barred from selling their disputed products. An amended lawsuit revealed that some samples tested were up to 33% impure. The new lawsuits target Aesthetic Maison, BOF Medical Center, DoctorsRx, G2 Telemedicine, GenericOzempic.com, MD Exam, MediOAK Pharmacy, Midtown Express, and Weight Loss MD. ...